GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Cash Ratio

Clarity Pharmaceuticals (ASX:CU6) Cash Ratio : 7.76 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Clarity Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 was 7.76.

Clarity Pharmaceuticals has a Cash Ratio of 7.76. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Clarity Pharmaceuticals's Cash Ratio or its related term are showing as below:

ASX:CU6' s Cash Ratio Range Over the Past 10 Years
Min: 7.76   Med: 11.01   Max: 57.9
Current: 7.76

During the past 2 years, Clarity Pharmaceuticals's highest Cash Ratio was 57.90. The lowest was 7.76. And the median was 11.01.

ASX:CU6's Cash Ratio is ranked better than
77.43% of 1524 companies
in the Biotechnology industry
Industry Median: 2.93 vs ASX:CU6: 7.76

Clarity Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Clarity Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Cash Ratio Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Cash Ratio
12.30 8.62

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial 37.70 12.30 9.72 8.62 7.76

Competitive Comparison of Clarity Pharmaceuticals's Cash Ratio

For the Biotechnology subindustry, Clarity Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Cash Ratio falls into.



Clarity Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Clarity Pharmaceuticals's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=65.015/7.542
=8.62

Clarity Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=37.983/4.894
=7.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals  (ASX:CU6) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Clarity Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (ASX:CU6) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines